Opinion|Videos|February 28, 2025
Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences
Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) while also considering how these factors align or differ from patient preferences regarding treatment duration, adverse effect profiles, and lifestyle impact.
Advertisement
Episodes in this series
- What clinical and patient-specific factors influence your treatment selection between BTK inhibitors for treatment-naive patients with CLL and MCL?
- How do your factors align with or differ from your patients’ preferences and values?
Advertisement
Related to this article
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
The Omaha-based practice will hand its inbound faxes and document management to artificial intelligence (AI) agents, with outside records retrieval to follow.
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
3
5 Things to Know if Retatrutide Is Classified as a Biologic
4
Will Cancer Care Come Home by 2030? PCOC Panelists Differ on Strategy
5